ursodiol

FDA Drug Profile — URSODIOL, URSOLIGN

ursodiol is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand names including URSODIOL, URSOLIGN. Available dosage forms: powder, capsule, tablet.

Drug Details

Generic Name
ursodiol
Brand Names
URSODIOL, URSOLIGN
Application Number
ANDA210344
Sponsor
Arch Pharmalabs Limited
NDC Codes
7
Dosage Forms
POWDER, CAPSULE, TABLET
Routes
ORAL
Active Ingredients
URSODIOL

Indications and Usage

INDICATIONS AND USAGE Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of Ursodiol beyond 24 months is not established. Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

Warnings

WARNINGS Enteroliths in Patients with Risk for Intestinal Stenosis or Stasis There have been rare postmarketing reports of ursodiol-treated patients who developed enteroliths (bezoars) resulting in obstructive symptoms that required surgical intervention. These patients had medical conditions that predisposed them to intestinal stenosis or stasis (e.g., surgical enteroanastomoses, Crohn's disease). If a patient presents with obstructive gastrointestinal symptoms, hold Ursodiol until a clinical evaluation has been conducted.